From July 22 to 24, 2026,TONACEA will host The 1st China Pharmaceutical Innovation Conference(CPIC 2026)at the National Exhibition and Convention Center (Shanghai).CPIC 2026 will establish a model of “China Innovation – Global Partnerships – Shanghai Dealmaking”.As the premier gateway for international capital to navigate China’s innovation ecosystem, and a strategic hub for Chinese pharmaceutical companies to scale globally, CPIC will undoubtedly set the benchmark for investment and partnership in the healthcare industry.CPIC will feature dozens of specialized sessions covering hot topics and future directions in healthcare innovation investment and globalization.Radiopharmaceuticals have emerged as a high-growth track fiercely pursued by global pharmaceutical giants. From diagnostics to therapeutics, and from radionuclide conjugation to precision targeting, this field is embracing unprecedented development opportunities. The full agenda for the "Booming Radiopharmaceuticals Session" is officially released today. This session will gather top scientists, clinical experts, and industry leaders to focus on core issues including isotope supply, drug design, clinical translation, and industrialization. Join us in Shanghai this July to explore the unlimited potential of the future of nuclear medicine.

Agenda

Opening Remarks
Yumin  Zhang: Founder, Anchoray Inc.; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)

Innovative Design of Radiopharmaceuticals
Zhen Cheng: Director, Molecular Imaging Center, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society for Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry, and International Association of Advanced Materials

Case Analysis of Preclinical Evaluation for Radiopharmaceuticals
Conglin Zuo: Founder, Hexin Pharmaceutical ; Vice Chairman, JOINN Laboratories; Member of the Drug Toxicology Committee, Chinese Pharmacological Society；Member, Drug Safety Evaluation Research Committee, Chinese Pharmaceutical Association

Clinical Development Strategies for Radiotherapeutic Drugs in Oncology
Yan Gong: General Manager, Honghong Pharma

Roundtable 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu(Moderator): Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li: Partner, Stars Capital
Chunguang Liu: Managing Partner, Tailong VC
Feng Yu: Founder & CEO, ELI Radiopharma

Roundtable 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li(Moderator): Party Secretary & Deputy Director, China Institute for Radiation Protection (CIRP)
Hong Liu: Chairman, Baiyunshan Rare Nuclide Health
Jim Cai: Chairman & CEO, New Radiomedicine Technology
Bo Shan: CEO, BoomRay Pharmaceuticals

Xiangsheng Ye: CSO, AlphaGen Therapeutics

Roundtable 3:What Big Pharma Seeks in Radiopharmaceuticals？
Wuzhou Wan: President, Central Research Institute, Yunnan Baiyao Group
Fang Li: Director, BD Search & Evaluation, Novartis China
Duan Wang: Director, Frontier Innovation Collaboration, Bayer Pharmaceuticals China Innovation Hub
(More guests to be confirmed...)